These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
75 related articles for article (PubMed ID: 24631189)
41. Design and synthesis of potent inhibitor of apoptosis (IAP) proteins antagonists bearing an octahydropyrrolo[1,2-a]pyrazine scaffold as a novel proline mimetic. Hashimoto K; Saito B; Miyamoto N; Oguro Y; Tomita D; Shiokawa Z; Asano M; Kakei H; Taya N; Kawasaki M; Sumi H; Yabuki M; Iwai K; Yoshida S; Yoshimatsu M; Aoyama K; Kosugi Y; Kojima T; Morishita N; Dougan DR; Snell GP; Imamura S; Ishikawa T J Med Chem; 2013 Feb; 56(3):1228-46. PubMed ID: 23298277 [TBL] [Abstract][Full Text] [Related]
42. Tethering identifies fragment that yields potent inhibitors of human caspase-1. Fahr BT; O'Brien T; Pham P; Waal ND; Baskaran S; Raimundo BC; Lam JW; Sopko MM; Purkey HE; Romanowski MJ Bioorg Med Chem Lett; 2006 Feb; 16(3):559-62. PubMed ID: 16274992 [TBL] [Abstract][Full Text] [Related]
43. Design and optimization of tricyclic phtalimide analogues as novel inhibitors of HIV-1 integrase. Verschueren WG; Dierynck I; Amssoms KI; Hu L; Boonants PM; Pille GM; Daeyaert FF; Hertogs K; Surleraux DL; Wigerinck PB J Med Chem; 2005 Mar; 48(6):1930-40. PubMed ID: 15771437 [TBL] [Abstract][Full Text] [Related]
44. Design and synthesis of benzofused heterocyclic RXR modulators. Gernert DL; Neel DA; Boehm MF; Leibowitz MD; Mais DA; Michellys PY; Rungta D; Reifel-Miller A; Grese TA Bioorg Med Chem Lett; 2004 Jun; 14(11):2759-63. PubMed ID: 15125928 [TBL] [Abstract][Full Text] [Related]
45. Design and synthesis of novel N-hydroxy-dihydronaphthyridinones as potent and orally bioavailable HIV-1 integrase inhibitors. Johnson TW; Tanis SP; Butler SL; Dalvie D; Delisle DM; Dress KR; Flahive EJ; Hu Q; Kuehler JE; Kuki A; Liu W; McClellan GA; Peng Q; Plewe MB; Richardson PF; Smith GL; Solowiej J; Tran KT; Wang H; Yu X; Zhang J; Zhu H J Med Chem; 2011 May; 54(9):3393-417. PubMed ID: 21446745 [TBL] [Abstract][Full Text] [Related]
46. Non-peptidic small molecule inhibitors of XIAP. Park CM; Sun C; Olejniczak ET; Wilson AE; Meadows RP; Betz SF; Elmore SW; Fesik SW Bioorg Med Chem Lett; 2005 Feb; 15(3):771-5. PubMed ID: 15664855 [TBL] [Abstract][Full Text] [Related]
47. Design of Potent pan-IAP and Lys-Covalent XIAP Selective Inhibitors Using a Thermodynamics Driven Approach. Baggio C; Gambini L; Udompholkul P; Salem AF; Aronson A; Dona A; Troadec E; Pichiorri F; Pellecchia M J Med Chem; 2018 Jul; 61(14):6350-6363. PubMed ID: 29940121 [TBL] [Abstract][Full Text] [Related]
48. Synthesis, SAR, and X-ray structure of tricyclic compounds as potent FBPase inhibitors. Tsukada T; Takahashi M; Takemoto T; Kanno O; Yamane T; Kawamura S; Nishi T Bioorg Med Chem Lett; 2009 Oct; 19(20):5909-12. PubMed ID: 19762234 [TBL] [Abstract][Full Text] [Related]
49. Expedient synthesis of highly potent antagonists of inhibitor of apoptosis proteins (IAPs) with unique selectivity for ML-IAP. Vamos M; Welsh K; Finlay D; Lee PS; Mace PD; Snipas SJ; Gonzalez ML; Ganji SR; Ardecky RJ; Riedl SJ; Salvesen GS; Vuori K; Reed JC; Cosford ND ACS Chem Biol; 2013 Apr; 8(4):725-32. PubMed ID: 23323685 [TBL] [Abstract][Full Text] [Related]
50. Structure-activity relationship of 6-methylidene penems bearing tricyclic heterocycles as broad-spectrum beta-lactamase inhibitors: crystallographic structures show unexpected binding of 1,4-thiazepine intermediates. Venkatesan AM; Gu Y; Dos Santos O; Abe T; Agarwal A; Yang Y; Petersen PJ; Weiss WJ; Mansour TS; Nukaga M; Hujer AM; Bonomo RA; Knox JR J Med Chem; 2004 Dec; 47(26):6556-68. PubMed ID: 15588091 [TBL] [Abstract][Full Text] [Related]
51. The discovery of tricyclic pyridone JAK2 inhibitors. Part 1: hit to lead. Siu T; Kozina ES; Jung J; Rosenstein C; Mathur A; Altman MD; Chan G; Xu L; Bachman E; Mo JR; Bouthillette M; Rush T; Dinsmore CJ; Marshall CG; Young JR Bioorg Med Chem Lett; 2010 Dec; 20(24):7421-5. PubMed ID: 21044843 [TBL] [Abstract][Full Text] [Related]
52. Development of novel azabenzofuran TRPA1 antagonists as in vivo tools. Copeland KW; Boezio AA; Cheung E; Lee J; Olivieri P; Schenkel LB; Wan Q; Wang W; Wells MC; Youngblood B; Gavva NR; Lehto SG; Geuns-Meyer S Bioorg Med Chem Lett; 2014 Aug; 24(15):3464-8. PubMed ID: 24953819 [TBL] [Abstract][Full Text] [Related]
53. A versatile enantioselective synthesis of barrenazines. Peña-López M; Martínez MM; Sarandeses LA; Sestelo JP Org Lett; 2010 Feb; 12(4):852-4. PubMed ID: 20092355 [TBL] [Abstract][Full Text] [Related]
54. Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins. Hay MP; Hicks KO; Pchalek K; Lee HH; Blaser A; Pruijn FB; Anderson RF; Shinde SS; Wilson WR; Denny WA J Med Chem; 2008 Nov; 51(21):6853-65. PubMed ID: 18847185 [TBL] [Abstract][Full Text] [Related]
55. C-H Arylation in the Formation of a Complex Pyrrolopyridine, the Commercial Synthesis of the Potent JAK2 Inhibitor, BMS-911543. Fox RJ; Cuniere NL; Bakrania L; Wei C; Strotman NA; Hay M; Fanfair D; Regens C; Beutner GL; Lawler M; Lobben P; Soumeillant MC; Cohen B; Zhu K; Skliar D; Rosner T; Markwalter CE; Hsiao Y; Tran K; Eastgate MD J Org Chem; 2019 Apr; 84(8):4661-4669. PubMed ID: 30388009 [TBL] [Abstract][Full Text] [Related]
56. Design and synthesis of tricyclic derivatives as high density lipoprotein cholesterol enhancers. Elokdah H; Chai SY; Ho D; Sulkowski T Bioorg Med Chem Lett; 2001 Feb; 11(3):339-42. PubMed ID: 11212105 [TBL] [Abstract][Full Text] [Related]
57. Phyllostictine A: total synthesis, structural verification and determination of substructure responsible for plant growth inhibition. Riemer M; Uzunova VV; Riemer N; Clarkson GJ; Pereira N; Napier R; Shipman M Chem Commun (Camb); 2018 Jun; 54(52):7211-7214. PubMed ID: 29897060 [TBL] [Abstract][Full Text] [Related]
58. Synthesis of BF2 chelates of tetraarylazadipyrromethenes and evidence for their photodynamic therapeutic behaviour. Killoran J; Allen L; Gallagher JF; Gallagher WM; O'Shea DF Chem Commun (Camb); 2002 Sep; (17):1862-3. PubMed ID: 12271646 [TBL] [Abstract][Full Text] [Related]
59. A formal total synthesis of roseophilin: cyclopentannelation approach to the macrocyclic core. Harrington PE; Tius MA Org Lett; 1999 Aug; 1(4):649-51. PubMed ID: 10823195 [TBL] [Abstract][Full Text] [Related]
60. Development of XIAP Antagonists Based On De Novo 8,5-Fused Bicyclic Lactams. Sheng ZJ; Shi YM; Xu X; Bellynck S; Zhang K; Du ZY; Xu X; Maurel F; Dong CZ ChemistryOpen; 2019 Jan; 8(1):34-40. PubMed ID: 30652062 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]